Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Capital Expenditures for 8 consecutive years, with $434000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 7.07% year-over-year to $434000.0; the TTM figure through Mar 2026 stood at $7.1 million (up 20.8% YoY), while the FY2025 annual figure was $7.2 million, down 44.2% from the prior year.
• Capital Expenditures retreated to $434000.0 in Q1 2026 per KYMR's latest filing, from $5.8 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $10.8 million in Q2 2023 and bottomed at -$14.8 million in Q3 2023.
• Historically, Capital Expenditures has averaged $1.2 million across 5 years, with a median of $695000.0 in 2025.
• On a YoY basis, Capital Expenditures climbed as much as 1365.03% in 2023 and fell as far as 1285.96% in 2023.
• Kymera Therapeutics' Capital Expenditures stood at -$1.5 million in 2022, then soared by 37.95% to -$909000.0 in 2023, then surged by 202.97% to $936000.0 in 2024, then soared by 521.9% to $5.8 million in 2025, then plunged by 92.54% to $434000.0 in 2026.
• Business Quant data shows KYMR's Capital Expenditures at $434000.0 in Q1 2026, $5.8 million in Q4 2025, and $181000.0 in Q3 2025.